Rapid Readouts

HSCT With Omidubicel Achieved Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to UCB Transplantation

February 24th 2022

Expert hematologist/oncologist Paul Szabolcs, MD, reviews positive data from a clinical trial comparing hematopoietic stem cell transplantation and omidubicel with standard cord blood transplantation.

Rapid Readouts

HSCT With Omidubicel Achieved Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to UCB Transplantation

Trending on CGTlive®

PreBLA Meeting With FDA Sinks uniQure’s Hopes for Approval of Huntington Disease Gene Therapy AMT-130 Based Primarily on Phase 1/2 Data

FDA Activity Recap: October 2025 Features New Platform Technology Designation, RDEA Pilot Program Selection, and More

Data Roundup: October 2025 Features Updates from ESMO, ESGCT, and More